Silence Therapeutics Free Cash Flow (FCF) History (SLN)

Silence Therapeutics reported −$62.3M in free cash flow for fiscal 2025, an increase of $5.5M from the previous fiscal year, with a free cash flow margin of −11149.55%.

View full Silence Therapeutics company overview

Silence Therapeutics free cash flow by year

Silence Therapeutics annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31−$62.3M$5.5M−11149.55%
20242024-12-31−$67.9M−$18.3M−156.85%
20232023-12-31−$49.5M$7.7M−156.49%
20222022-12-31−$57.2M−264.22%

Silence Therapeutics free cash flow growth trends

Silence Therapeutics's latest reported quarter, Q2 2026, generated $1.5M in free cash flow, an increase of $23.4M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Silence Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about SLN yet. Start the conversation.

Write the first post